Bernstein raised its price target on UnitedHealth Group Incorporated to $492 from $444 on May 27 and kept an Outperform rating, a move the firm said reflects an improved adjusted EPS outlook tied to a recovery in Medicare Advantage.
The new $492 target—up from $444—implies roughly 27% upside potential from the baseline the analysts used, an unusually large single-step lift that follows a separate upgrade from Barclays the day before.
On May 26 Barclays raised its price target on UNH to $429 from $373 and maintained an Overweight rating, saying it sees the stock moves across managed care companies after Q1 earnings reports as durable. Together the two banks pushed three-figure target increases in a two-day span.
Bernstein pointed specifically to a projected 16% adjusted EPS compound annual growth rate as the driver behind its willingness to assign a higher valuation multiple during what it calls a cyclical recovery phase. That forecast is the explicit rationale Bernstein offered for moving to $492 and preserving its Outperform stance.
Barclays framed its May 26 action around the sector picture. The firm said the post–Q1 performance across managed care is not a short-term blip and signaled a preference for insurers over providers, keeping an Overweight call on UNH as it raised its target to $429 from $373.
That preference matters because Barclays also notes it continues to favor managed care companies over healthcare facilities, citing rising inflation and changes in commercial mix as growing sources of earnings risk for provider businesses. Those risks, Barclays said, place a premium on firms whose revenue and margins benefit from scale and diversified services.
UnitedHealth Group Incorporated combines insurance and services businesses that map to that thesis: the company’s operating segments include Optum Health, Optum Insight, Optum Rx and UnitedHealthcare. Analysts at both firms framed their target changes partly by how those businesses could perform if Medicare Advantage participation and profitability recover as expected.
The practical implication for shareholders is straightforward: two influential research shops raised price targets within 24 hours, broadening the analyst range around UNH stock and underscoring bullish expectations for Medicare Advantage-driven earnings. Bernstein’s $492 target sits at the top of that updated range; Barclays’ $429 establishes a nearer-term floor the firms are willing to defend.
The unresolved question is how markets will translate those targets into price action over coming sessions. The reports do not quantify how much upward momentum the new targets will produce, and whether additional firms will follow with higher estimates remains open. The next meaningful test will be whether UnitedHealth’s upcoming results and Medicare Advantage trends validate the 16% adjusted EPS CAGR that underpins Bernstein’s higher multiple.
